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Abstract 
Background/Purpose: Orbital atherectomy is an effective treatment strategy to modify severely 
calcified coronary lesions prior to stent placement.  Traversing a severely calcified subtotal 
occlusion with the crown may be more challenging compared with a less severely stenotic lesion.   
The purpose of this ORBIT II subanalysis was to evaluate outcomes post-orbital atherectomy 
(OA) treatment of lesions with ≥95% stenosis. 
Methods/Materials: ORBIT II, a single-arm, prospective, multicenter trial, enrolled 443 
subjects with severely calcified coronary lesions. Patients with chronic total occlusions were 
excluded from the trial. Subjects with the OA device activated were stratified based on pre-
procedure percent stenosis: ≥95% stenosis (N=91) and <95% stenosis (N=341). Procedural 
success and 3-year major adverse cardiac event (MACE) rates were compared.  
Results: The severe angiographic complications rates were 6.6% and 6.7% in the ≥95% and 
<95% stenosis groups, respectively. There was no significant difference in procedural success 
(94.5% vs. 88.3%, p=0.120). 3-year MACE rates were similar (27.1% vs. 22.5%, p=0.548), as 
were the rates of cardiac death (5.7% vs. 7.1%, p=0.665) and MI (7.9% vs. 12.1%, p=0.244). The 
TVR rate was higher in the ≥95% stenosis group (19.1% vs. 7.5%, p=0.004).  
Conclusions: In ORBIT II, OA treatment of lesions with ≥95% stenosis resulted in a high rate of 
procedural success. Although the 3-year revascularization rate was higher in the ≥95% stenosis 
group, it is not unexpected given the challenge of treating such complex lesions. The results of 
this analysis suggest that OA may be a reasonable treatment strategy for tight, severely calcified 
subtotal occlusions. 
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Summary: The purpose of this ORBIT II subanalysis was to evaluate outcomes post-orbital 
atherectomy (OA) treatment of lesions with ≥95% stenosis. In ORBIT II, OA treatment of 
lesions with ≥95% stenosis resulted in a high rate of procedural success. Although the 3-year 
revascularization rate was higher in the ≥95% stenosis group, it is not unexpected given the 
challenge of treating such complex lesions. The results of this analysis suggest that OA may be a 
reasonable treatment strategy for tight, severely calcified subtotal occlusions. 
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Abbreviations: 
ACC = American College of Cardiology 
AHA = American Heart Association 
CTO = chronic total occlusion 
eGFR = estimated glomerular filtration rate 
IVUS = intravascular ultrasound 
LAD = left anterior descending artery 
MACE = major adverse cardiac events 
MI = myocardial infarction 
MLD = minimal luminal diameter 
PCI = percutaneous coronary intervention 
OA = orbital atherectomy 
OAS = orbital atherectomy system 
RCA = right coronary artery 
RVD = reference vessel diameter 
TLR = target lesion revascularization 
TVR = target vessel revascularization 
ULN = upper limit of lab normal 
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Introduction 
Coronary artery calcification is commonly observed in patients who undergo coronary 
angiography, as 73% of lesions contained calcification based upon intravascular ultrasound 
(IVUS).[1]  Percutaneous coronary intervention (PCI) of severely calcified coronary artery 
lesions is technically challenging due to difficulty in advancing stents and achieving optimal 
stent expansion. [2] This may explain why PCI of severely calcified lesions is associated with 
higher rates of ischemic complications.[3] 
Coronary atherectomy effectively modifies calcified plaque, facilitating stent delivery 
and expansion.  In the ORBIT II trial, the Diamondback 360
®
 Coronary Orbital Atherectomy 
System (OAS, Cardiovascular Systems, Inc., St. Paul, MN) was a safe and effective treatment 
strategy for severely calcified coronary lesions prior to stent delivery at 30-day and 3-year 
follow-up.[4,5]  
The presence of calcium in chronic total occlusions (CTO) is common; calcified CTO 
PCI is associated with high complication rates.[6] There is no published data regarding orbital 
atherectomy (OA) treatment of CTOs or tight subtotal occlusions. Subtotal (≥95% stenosis) 
occlusions may be more complex to treat due to difficulty in traversing the lesion with the OA 
crown compared with lesions that are not subtotally occluded.  The purpose of this ORBIT II 
subanalysis was to evaluate outcomes post-OA treatment of lesions with ≥95% stenosis. 
 
Material and methods 
Study design.  ORBIT II was a prospective, non-blinded, single-arm, clinical trial that enrolled 
443 consecutive subjects with severely calcified coronary lesions from 49 U.S. centers.[4]  Key 
trial inclusion criteria included: (1) target vessel reference diameter between 2.5 to 4 mm with a 
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stenosis ≥70% and <100% or stenosis ≥50% and <70% with evidence of clinical ischemia via  
IVUS minimum lumen area ≤4.0 mm2, fractional flow reserve value ≤0.8, or positive stress test; 
(2) target lesion length ≤40 mm; and (3) evidence of severe calcium deposit at the lesion site 
defined as presence of angiographic radio-opacities noted without cardiac motion prior to 
contrast injection involving both sides of the arterial wall in at least one location, total calcium 
length ≥15 mm that extends partially into the target lesion, or presence of ≥270° of calcium on 
IVUS at one cross section. Key exclusion criteria included: (1) acute myocardial infarction (MI) 
(defined as creatine kinase-MB [CK-MB] >1× upper limit of lab normal (ULN) within 30 days 
of the index procedure); (2) target vessel with stent from previous PCI unless the stent was in a 
different branch than the target lesion and was implanted over 30 days prior with no higher than 
30% in-stent restenosis; (3) chronic renal failure unless undergoing hemodialysis, or had a serum 
creatinine level >2.5 mg/dl; and (4) left ventricular ejection fraction ≤25%. The use of advanced 
intracoronary imaging was not required as part of the ORBIT II study protocol and was left to 
operator discretion. All participants provided informed consent and the study was approved by 
each institutional review/ethics committee. Subject follow-up included a clinic visit at 30 days 
and telephone call or clinic visit at 1, 2, and 3 years post procedure. 
Study population. Subjects with the OA device activated were stratified according to pre-
procedure percent stenosis as assessed by the Investigator: ≥95% stenosis (N=91) and <95% 
stenosis (N=341).  
Study device. The mechanism of OA is differential sanding, in which calcified plaque is 
modified while it flexes away from healthy softer tissue.  The eccentrically mounted diamond-
coated crown spins over the ViperWire (Cardiovascular Systems, Inc.) and expands radially via 
centrifugal force. Increasing the time in contact with the lesion, number of passes, and rotational 
ACCEPTED MANUSCRIPT
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on September 17, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IPT
8 
 
speed increase luminal gain as the crown is moved back and forth across the lesion.  The 
elliptical orbit permits blood and micro-debris to flow past the crown, which continuously 
disperses the particulate.  The ViperSlide (Cardiovascular Systems, Inc.) solution is infused into 
the drive shaft to cool the crown and reduce the risk of thermal injury to the target vessel.   
Study outcomes. Procedural success was defined as successful stent delivery with a final 
residual stenosis of < 50% and without in-hospital major adverse cardiac events (MACE). 
MACE was defined as the composite of cardiac death, MI, and target vessel 
revascularization/target lesion revascularization (TVR/TLR).  Myocardial infarction was defined 
as creatine kinase-myocardial band level > 3 times upper limit of normal with or without a new 
pathologic Q-wave. Target vessel revascularization was defined as repeat revascularization of the 
target vessel (inclusive of the target lesion) after completion of the index procedure. MACE was 
defined as the composite of cardiac death, MI, and TVR. The angiographic core laboratory 
(Cleveland Clinic Foundation, Cleveland, Ohio) analyzed the procedural angiograms and 
reported the final minimum lumen diameter and final percentage of residual stenosis as well as 
the presence and type of dissections and perforations. 
Statistical analysis. Continuous variables are presented as mean ± standard deviation and 
categorical variables are presented as percentages.  The two groups were compared using the 
Wilcoxon rank-sum test for continuous parameters and Fisher’s exact test for categorical 
parameters.  A Kaplan-Meier analysis with a confidence interval based on Peto’s method was 
used to estimate the MACE rate as well as the individual components including cardiac death, 
MI, and TVR. Statistical comparisons of the Kaplan-Meier event rates were made using Cox 
proportional hazards model. Multivariable Cox proportional hazards regression was performed to 
identify independent predictors of 3-year TVR. Covariates in the model included: age, history of 
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diabetes mellitus, smoking history (current/former vs. never), history of MI, history of coronary 
artery bypass grafting, eGFR (<50 vs. ≥50), left ventricular ejection fraction, pre-procedure 
reference vessel diameter (RVD), target lesion length, pre-procedure stenosis (≥95% vs. <95%), 
bare metal stent vs. drug eluting stent, number of stents, and ratio of highest stent diameter to 
RVD.  The entry criteria in the multivariable model was an alpha level of 0.20; significant 
predictors of outcomes in the final multivariable model were identified at a 0.05 alpha. Statistical 
analyses were performed with either SAS software system (SAS Institute, Inc) or R (R Core 
Team 2012; R Foundation for Statistical Computing). 
 
Results 
Subject demographics and lesion characteristics. Subjects with ≥95% stenosis were older 
(74.2 ± 9.1 years vs. 70.8 ± 10.0 years, p=0.003) and had lower eGFR (70.5 ± 24.5 mL/min/1.73 
m
2
 vs. 77.0 ± 26.7 mL/min/1.73 m
2
, p=0.042) (Table 1). Otherwise, the groups were well 
matched in terms of baseline demographics. As shown in Table 2, compared with the <95% 
stenosis group, in the ≥95% stenosis there were fewer left anterior descending (LAD) lesions 
(35.2% vs. 56.6%, p<0.001) and more right coronary artery (RCA) lesions (45.1% vs. 25.2%, 
p<0.001). Additionally, there were fewer Type B1 lesions in the ≥95% stenosis group (17.6% vs. 
28.2%, p=0.044). The mean pre-procedure percent stenosis was 96.1% and 81.1%, in the ≥95% 
and <95% stenosis groups, respectively (p<0.001).   
Procedural and angiographic results. Procedural parameters are presented in Table 3. 
Compared with the <95% stenosis group, the ≥95% stenosis group had a smaller post-OAS 
minimal luminal diameter (1.0 ± 0.6 mm vs. 1.3 ± 0.5, p<0.001), higher post-OAS residual 
percent stenosis (66.2 ± 19.1% vs. 56.7 ± 16.3%, p<0.001), higher usage of drug-eluting stents 
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(95.0% vs. 86.8%, p=0.013), and a higher maximum stent deployment pressure (14.6 ± 3.3 atm 
vs. 13.6 ± 3.1 atm, p=0.006).  Stents in the <95% stenosis group were significantly shorter in 
length (20.2 ± 7.3 mm vs. 22.3 ± 7.7 mm, p=0.006) and significantly larger in diameter (3.0 ± 
0.4 mm vs. 2.9 ± 0.4 mm, p=0.020). Procedural success was 94.5% and 88.3% in the ≥95% 
stenosis and <95% stenosis groups, respectively (p=0.120). The in-hospital MI rate (CK-MB > 
3X ULN) was higher in the <95% stenosis group (3.3% vs. 11.1%, p=0.025); however, the MI 
rates did not differ using the more clinically-relevant SCAI MI definition (≥95% stenosis: 1.1% 
vs. <95% stenosis: 2.3%, p=0.692).[7] The overall severe angiographic complication rates were 
nearly identical in both groups (6.6% vs. 6.7%, p>0.99) (Table 4).  
30-day and 3-year MACE. There was no difference in the 30-day MACE rate in the ≥95% 
stenosis and <95% stenosis groups (5.5% vs. 11.7%, p=0.099), or in the components of cardiac 
death (0% vs. 0.3, p=0.997) and TVR/TLR (2.2% vs. 0.9%, p=0.319) (Table 5, Figure 1).  
However, the MI rate at 30 days was lower in the ≥95% stenosis group (3.3% vs. 11.4%, 
p=0.035).  At 3-year follow-up, the MACE rates were similar in both groups (27.1% vs. 22.5%, 
p=0.55), as were the rates of cardiac death (5.7% vs. 7.1%, p=0.665) and MI (7.9% vs. 12.1%, 
p=0.244).  However, the 3–year TVR/TLR rate was higher in the ≥95% stenosis group (19.1% 
vs. 7.5%, p=0.004). The final multivariable model identified ≥95% stenosis group [HR 2.87 
(95% CI: 1.49, 5.53), p=0.002], bare metal stent usage [HR 2.95 (95% CI: 1.19, 7.28), p=0.019], 
and pre-procedure RVD [HR 0.13 (95% CI: 0.02, 0.76), p=0.024] as independent predictors of 3-
year TVR (Table 6).    
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Discussion 
In the only analysis of its kind, the results of our analysis suggest that OA is a feasible 
and safe treatment for patients with severely calcified subtotal occlusions both at short and long-
term follow-up.  However, the TVR rate at 3 years was higher in the ≥95% stenosis group.  
Percutaneous coronary intervention of heavily calcified coronary artery lesions that are 
severely stenotic may be technically more challenging compared to less stenotic lesions.  
Severely calcified lesions that are subtotally occluded may lead to procedural failure due to the 
inability to cross the lesion.  More aggressive advancement of the classic crown may be required 
to successfully traverse the lesion.  Despite the mean pre-procedure minimum luminal diameter 
of 0.1 mm in the ≥95% stenosis group, the procedural success rate was 94.5%, which fared well 
compared with the <95% stenosis group (88.3%).  The rate of severe angiographic complications 
was nearly identical in both groups.  Despite the higher percent stenosis, the OA crown was able 
to treat the subtotal occlusion without a higher complication rate.  In particular, the rate of 
persistent slow flow/no reflow was 1.1% even though the plaque burden was high in the ≥95% 
stenosis group. The perforation rate was numerically higher in the ≥95% stenosis group (3.3% 
vs. 1.5%, p=0.374). Proper OA technique, including slow advancement of the crown (1 mm/s), 
may reduce the risk of perforation.[8,9] The in-hospital MI rate (CK-MB > 3X ULN) was 
significantly lower in the ≥95% stenosis group; however, when calculated using the SCAI MI 
definition which includes a cardiac biomarker elevation threshold which has been strongly linked 
to adverse clinical outcomes, the MI rates were similar in both groups.[7]  
The ≥95% stenosis group had a higher 3-year TVR rate; as shown in the multivariable 
analysis, ≥95% stenosis group, bare metal stent usage, and decreasing pre-procedure RVD were 
independent predictors of 3-year TVR. The ≥95% stenosis group required a higher maximum 
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deployment pressure, which is also consistent with the larger plaque volume.  Despite this, the 3-
year TVR/TLR rate of 19.1% in the ≥95% stenosis group compares favorably with the results of 
the 2-year TVR rate in patients who underwent rotational atherectomy in the ROTAXUS trial 
(19.3%), albeit differences in level of calcification and types of stents used.[10]  There is no 
published rotational atherectomy study that stratified by lesion stenosis severity.   
Several techniques can be utilized to enhance successful passage of the OA crown across 
subtotal occlusions.  Optimal co-axial guide catheter positioning can provide the sufficient 
support to traverse the lesion.  Placement of the ViperWire at the distal portion of the vessel 
increases stability and anchoring, providing an optimal “rail system.”  Placement of the crown 
partially into the lesion at initial activation, but not tight or fully occlusive, may facilitate 
crossing.  A slow and steady advancement of the crown at 1mm/sec is preferred rather than 
rapidly engaging the lesion. Lastly, the use of a guide extension catheter, such as a Guideliner 
(Vascular Solutions, Minneapolis, MN), may facilitate procedural success by supporting the 
guide catheter.  Additional OAS techniques and best practices can be found in recently published 
review articles.[8,9,11,12]  
 
Study Limitations 
This was a post-hoc subanalysis of ORBIT II—a non-randomized pivotal trial. The ≥95% 
stenosis cohort had a small number of subjects and the pre-procedure stenosis was reported by 
the Investigator via angiography.  A stenosis of ≥95% may not be universally accepted as a 
subtotal occlusion.  
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Conclusions  
In the ORBIT II trial, OA treatment of lesions with ≥95% stenosis resulted in a high rate 
of procedural success. Although the 3-year revascularization rate was higher in the ≥95% 
stenosis group, it is not unexpected given the challenge of treating such complex lesions. The 
results of this analysis suggest that OA may be a reasonable treatment strategy for PCI of tight, 
severely calcified subtotal occlusions. 
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Figure Legend 
Figure 1. Time-to-Event Curves through 3 Years. 
Comparison of the cumulative event rates through 3-year follow-up in ORBIT II subjects with 
≥95% pre-procedure stenosis (N=91) and <95% pre-procedure stenosis (N=341). (A) Major 
adverse cardiac events. (B) Cardiac death. (C) Myocardial infarction. (D) Target vessel 
revascularization. 
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Table 1. Subject Demographics. 
 
 
≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Age (years) 74.2 ± 9.1 70.8 ± 10.0 0.003 
Male 56 (61.5) 222 (65.1) 0.540 
Ethnicity   0.116 
Caucasian 85 (93.4) 297 (87.1)  
Black or African American 2 (2.2) 21 (6.2)  
Asian 0 (0.0) 8 (2.3)  
Hispanic or Latino 2 (2.2) 13 (3.8)  
Native American 0 (0.0) 1 (0.3)  
Other 2 (2.2) 1 (0.3)  
Body mass index 29.3 ± 6.2 29.3 ± 5.7 0.452 
eGFR (mL/min/1.73 m
2
) 70.5 ± 24.5 
(N=90) 
77.0 ± 26.7 
(N=340) 
0.042 
eGFR <30 mL/min/1.73 m
2
 4 (4.4) 10 (2.9) 0.504 
eGFR 30-50 mL/min/1.73 m
2
 13 (14.4) 27 (7.9) 0.067 
eGFR >50 mL/min/1.73 m
2
 73 (81.1) 303 (89.1) 0.049 
History of:    
Diabetes mellitus 28 (30.8) 127 (37.2) 0.271 
Hypertension 82 (90.1) 313 (91.8) 0.673 
Dyslipidemia 83 (91.2) 315/340 (92.6) 0.658 
Stroke/transient ischemic attack 9 (9.9) 30/340 (8.8) 0.837 
Myocardial infarction 18/88 (20.5) 76/339 (22.4) 0.774 
Angina 69 (75.8) 270 (79.2) 0.477 
Stable 48/69 (69.6) 169/270 (62.6)  
Unstable 21/69 (30.4) 101/270 (37.4)  
Prior percutaneous coronary intervention 38 (41.8) 160/337 (47.5) 0.346 
Prior coronary artery bypass grafting 18 (19.8) 46 (13.5) 0.138 
Left ventricular ejection fraction (%) 56.1 ± 10.9 56.7 ± 9.2 
(N=335) 
0.884 
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≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Smoking   0.281 
No, Never smoked 30 (33.0) 114 (33.4)  
Yes, Current smoker 10 (11.0) 60 (17.6)  
Yes, Former smoker 51 (56.0) 167 (49.0)  
Values are n (%) or mean ± standard deviation 
eGFR = estimated glomerular filtration rate 
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Table 2. Vessel & Lesion Characteristics. 
 
 
≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Target lesion vessel    
Left anterior descending artery 32 (35.2) 193 (56.6) <0.001 
Left circumflex artery 14 (15.4) 49 (14.4) 0.867 
Left main coronary artery 4 (4.4) 6 (1.8) 0.229 
Right coronary artery 41 (45.1) 86 (25.2) <0.001 
Ramus 0 (0.0) 7 (2.1) 0.354 
Pre-procedure target lesion length (mm) 20.4 ± 9.2 18.5 ± 8.8 0.062 
Pre-procedure average reference vessel diameter (mm) 3.0 ± 0.4 3.1 ± 0.4 0.047 
ACC/AHA lesion classification    
A 0 (0.0) 0 (0.0) —  
B1 16 (17.6) 96 (28.2) 0.044 
B2 42 (46.2) 153 (44.9) 0.906 
C 33 (36.3) 92 (27.0) 0.091 
Pre-procedure minimum luminal diameter (mm) 0.1 ± 0.1 0.6 ± 0.2 <0.001 
Pre-procedure percent stenosis (%) 96.1 ± 1.8 81.1 ± 7.3 <0.001 
Subjects with calcification determined by angiography 
only 
90 (98.9) 307 (90.0) 0.004 
Total length of calcium (including segmented) 
(mm) 
29.9 ± 14.5 28.0 ± 15.5 0.124 
Subjects with calcium visible on both sides of the 
vessel 
90 (100.0) 307 (100.0) >0.99 
Subjects with calcification determined by IVUS 1 (1.1) 34 (10.0) 0.004 
Maximum degree of calcium via IVUS (°) 360.0 ± 0 293.1 ± 35.1 0.152 
Values are n (%) or mean ± standard deviation 
ACC = American College of Cardiology, AHA = American Heart Association, IVUS = intravascular 
ultrasound 
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Table 3. Final Overall Procedural Results. 
 
 
≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
OAS speed(s) used (rpm)   0.766 
Low only (80,000) 17 (18.7) 76 (22.3)  
Low and high (80,000/120,000) 70 (76.9) 247 (72.4)  
High only (120,000) 4 (4.4) 18 (5.3)  
Average individual device run time (seconds) 19.2 ± 6.5 
(N=90) 
19.6 ± 5.4 
(N=340) 
0.831 
Total device run time (seconds) 75.3 ± 62.8 64.5 ± 39.6 
(N=340) 
0.658 
Post-OAS minimal luminal diameter (mm) 1.0 ± 0.6 1.3 ± 0.5 <0.001 
Post-OAS residual stenosis (%) 66.2 ± 19.1 56.7 ± 16.3 <0.001 
Subjects treated with post-OAS/pre-stent balloon dilations 44 (48.4) 133 (39.0) 0.119 
Post-OAS/pre-stent balloons used per subject 1.4 ± 0.8 
(N=44) 
1.4 ± 0.8 
(N=133) 
0.668 
Maximum inflation pressure (atmospheres) 12.0 ± 3.4 
(N=44) 
12.0 ± 4.1 
(N=132) 
0.716 
Time at maximum pressure (seconds) 30.7 ± 30.4 
(N=44) 
26.4 ± 21.6 
(N=131) 
0.709 
Post-OAS balloon angioplasty MLD (mm) 1.6 ± 0.7 
(N=44) 
1.9 ± 0.6 
(N=131) 
0.095 
Post-OAS balloon angioplasty residual stenosis (%) 46.3 ± 22.3 
(N=44) 
40.5 ± 19.5 
(N=131) 
0.136 
Subjects with stent placed 89 (97.8) 338 (99.1) 0.284 
Post-OAS stents used per subject 1.3 ± 0.6 
(N=89) 
1.2 ± 0.6 
(N=338) 
0.046 
Types of stents used in study    
Bare metal stent 5/119 (4.2) 54/417 (12.9) 0.007 
Covered stent 1/119 (0.8) 1/417 (0.2) 0.395 
Drug-eluting stent 113/119 (95.0) 362/417 (86.8) 0.013 
Stent length* (mm) 22.3 ± 7.7 
(N=115) 
20.2 ± 7.3 
(N=405) 
0.006 
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≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Stent diameter* (mm) 2.9 ± 0.4 
(N=115) 
3.0 ± 0.4 
(N=405) 
0.020 
Ratio of highest stent diameter to reference vessel 
diameter* 
1.0 ± 0.1 
(N=89) 
1.0 ± 0.1 
(N=336) 
0.567 
Maximum deployment pressure (atmospheres) 14.6 ± 3.3 
(N=89) 
13.6 ± 3.1 
(N=336) 
0.006 
Post-stent residual stenosis (%) 5.7 ± 11.2 
(N=89) 
5.8 ± 11.9 
(N=337) 
0.958 
Final procedure MLD (mm) 2.8 ± 0.6 
(N=87) 
2.9 ± 0.5 
(N=330) 
0.546 
Final procedure stenosis (%) 5.7 ± 14.6 4.0 ± 13.8 
(N=340) 
0.298 
Total procedure time (minutes) 50.7 ± 31.9 52.0 ± 28.3 
(N=340) 
0.290 
Total fluoroscopy time (minutes) 19.5 ± 15.0 
(N=90) 
17.4 ± 10.8 
(N=338) 
0.426 
Total volume of contrast used (mL) 178.0 ± 93.7 
(N=90) 
171.1 ± 82.4 
(N=340) 
0.646 
Procedural success 86 (94.5) 301 (88.3) 0.120 
Successful stent delivery 89 (97.8) 336 (98.5) 0.642 
< 50% residual stenosis 90 (98.9) 337 (98.8) >0.99 
In hospital MACE 4 (4.4) 39 (11.4) 0.049 
Cardiac death 0 (0.0) 1 (0.3) >0.99 
Myocardial infarction (CK-MB >3X ULN) 3 (3.3) 38 (11.1) 0.025 
Non Q-wave 3 (3.3) 35 (10.3) 0.037 
Q-wave 0 (0.0) 3 (0.9) >0.99 
TVR 1 (1.1) 2 (0.6) 0.509 
SCAI MI 1 (1.1) 8 (2.3) 0.692 
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≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Values are n (%) or mean ± standard deviation 
*Specific to stents successfully deployed 
MACE = major adverse cardiac event; MI = myocardial infarction; MLD = minimal luminal diameter; 
OAS = orbital atherectomy system; SCAI = Society for Cardiovascular Angiography and Interventions; 
TVR = target vessel revascularization 
 
 
  
ACCEPTED MANUSCRIPT
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on September 17, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
AC
CE
PT
ED
 M
AN
US
CR
IPT
23 
 
Table 4. Severe Angiographic Complications. 
 
≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
Severe angiographic complications 6 (6.6) 23 (6.7) >0.99 
Severe dissection (Type C, D, E, and F) 2 (2.2) 11 (3.2) >0.99 
Perforation 3 (3.3) 5 (1.5) 0.374 
Persistent slow flow/no reflow 1 (1.1) 2 (0.6) 0.509 
Abrupt closure 1 (1.1) 7 (2.1) >0.99 
Values are n (%) 
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Table 5. Cumulative MACE Rates (as estimated by Kaplan-Meier). 
 
≥95% pre-
procedure 
stenosis 
(N=91) 
<95% pre-
procedure 
stenosis 
(N=341) P-value 
30-day major adverse cardiac events 5.5 11.7 0.099 
Cardiac death 0 0.3 0.997 
Myocardial infarction (CK-MB >3X 
ULN) 
3.3 11.4 0.035 
Non Q-wave 3.3 10.3 0.056 
Q-wave 0 1.2 0.994 
TVR/TLR 2.2 0.9 0.319 
TLR 1.1 0.6 0.610 
TVR (non-TLR) 1.1 0.3 0.355 
3-year major adverse cardiac events 27.1 22.5 0.548 
Cardiac death 5.7 7.1 0.665 
Myocardial infarction (CK-MB >3X 
ULN) 
7.9 12.1 0.244 
Non Q-wave 6.6 10.9 0.236 
Q-wave 1.3 1.2 0.947 
TVR/TLR 19.1 7.5 0.004 
TLR 16.9 5.2 0.002 
TVR (non-TLR) 4.7 2.6 0.318 
Values are %  
MACE = major adverse cardiac events; TLR = target lesion revascularization; TVR = target 
vessel revascularization 
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Table 6. Analysis of Independent Predictors of 3-Year TVR 
 
Unadjusted Hazard 
Ratio (95% CI) P-value 
Adjusted Hazard 
Ratio (95% CI) 
P-value 
Pre-procedure stenosis (≥95% vs. <95%) 2.80 [1.47, 5.32] 0.002 2.87 [1.49, 5.53] 0.002 
Age (per 10 years) 1.00 [1.00, 1.00] 0.558   
History of diabetes mellitus 0.95 [0.49, 1.86] 0.885   
Current/former smoker 0.76 [0.40, 1.47] 0.419   
History of MI 0.86 [0.38, 1.97] 0.724   
History of coronary artery bypass grafting 0.91 [0.36, 2.33] 0.846   
eGFR (<50 vs. ≥50 mL/min/1.73 m2) 0.64 [0.20, 2.07] 0.452   
LVEF (per 10%) 1.00 [1.00, 1.00] 0.787   
Pre-procedure RVD (per 0.5 mm) 0.14 [0.02, 0.80] 0.027 0.13 [0.02, 0.76] 0.024 
Target lesion length (mm) 1.03 [0.99, 1.06] 0.098   
Bare metal stent vs. drug-eluting stent 1.95 [0.81, 4.66] 0.134 2.95 [1.19, 7.28] 0.019 
Number of stents 0.97 [0.48, 1.96] 0.937   
Ratio of highest stent diameter to RVD 0.03 [0.00, 2.96] 0.136   
eGFR = estimated glomerular filtration rate; LVEF = left ventricular ejection fraction; MI = myocardial 
infarction; RVD = reference vessel diameter; TVR = target vessel revascularization 
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Highlights 
 Outcomes post-OA treatment of severely calcified ≥95% stenosis lesions were assessed 
 Procedural success and 3-year MACE were similar in ≥95% and <95% stenosis groups 
 Higher 3-year TVR in ≥95% stenosis group not unexpected given challenge of treating 
such complex lesions 
 OA may be a reasonable treatment strategy for tight, severely calcified subtotal 
occlusions 
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